•Aetna (Hartford, Connecticut) reported that it has reached agreement with the Central Florida Health Alliance (Orlando) on a three-year contract that adds Leesburg Regional Medical Center (Leesburg, Florida) and The Villages Regional Hospital (Villages, Florida) to Aetna's provider network in the Central Florida area. The agreement takes effect Sept. 15. Under the agreement, members of Aetna network-based plans will be able to receive covered inpatient and outpatient services, at in-network rates, from Leesburg Regional Medical Center and The Villages Regional Hospital. Aetna provides and administers health benefits to more than 225,000 members in Central Florida. Those members have access to a contracted network of 35 hospitals, 1,626 primary care physicians and 4,434 specialists. The Villages Regional Hospital, part of Central Florida Health Alliance, is a 198-bed, acute-care hospital located in the heart of The Villages, a nationally-known adult community. The facility serves the tri county area Lake, Sumter and south Marion counties. Leesburg Regional Medical Center, also part of Central Florida Health Alliance, is a 309-bed, acute-care hospital with specialty services including comprehensive cardiovascular, neurosurgery, and the only designated stroke center with the Joint Commission Seal of Approval in Lake and Sumter counties.

•Hatch Medical (Duluth, Georgia), a medical device incubator and technology brokerage firm, said it has agreed to broker Evexar Medical's (Bromley, UK) self-expanding, collagen-based sealing technology, EndoSeal. According to Evexar, Endovascular aortic repair was introduced in the mid 1990's as a minimally invasive alternative to open surgical repair and was aimed at reducing many of the associated risks with current surgical techniques. Unfortunately, while aortic endografts provide numerous benefits, complications often follow this procedure, the company said. One of the more significant complications is an endoleak, a condition often attributed to a poor seal between the endograft and the native vessel at its extremities. Such endoleaks, if left untreated, predictably result in ongoing pressure in the aneurysmal sac with the associated risk of rupture. Evexar says its technology effectively seals gaps that can occur between an endograft and an irregular vessel wall, ensuring a secure seal and substantially reducing the possibility of endoleaks. "We are very pleased to be working with Evexar Medical and believe that the EndoSeal technology will provide innumerable benefits and greater procedural options for clinicians, patients and endograft manufacturers by reducing the long-term complications associated with endograft placement," said Paul Gianneschi, managing principal and founder of Hatch Medical.

•Novation (Irving, Texas), a healthcare contracting services company of VHA (Irving, Texas), University HealthSystem Consortium (Oak Brook, Illinois) and Provista (Irving, Texas), said it has added Guidant cardiac rhythm management devices to its Boston Scientific (Natick Massachusetts) agreement. The Cognis CRT-D and the Teligen ICD are among the world's smallest and thinnest high-energy devices at 32.5 cc and 31.5 cc respectively, while less than 10 mm thick. Both devices offer features based on substantial engineering advances, including extended battery longevity over previous company devices, self-correcting software and improved programming technology. The contract addition was effective Aug. 1.

•OmniSonics Medical Technologies (Wilmington, Massachusetts), a developer of devices for use in the treatment of vascular disease, reported that it has entered into a licensing and development agreement with Boston Scientific (Natick, Massachusetts) for technology to treat thromboembolic acute ischemic stroke. Treatment of this type of stroke represents a significant unmet clinical need, as only 10% of the more than 600,000 stroke patients in the U.S. receive therapy each year, the companies said. The two companies will work jointly to develop an application of OmniSonics' OmniWave technology for the treatment of acute ischemic stroke. The OmniWave technology, which delivers low-power ultrasonic energy to remove thrombus (or a blood clot), recently was launched in the U.S. for the treatment of clots in the peripheral vasculature. Boston Sci will provide funding based on the achievement of development milestones and has an option to acquire the technology as well as exclusive rights to the intellectual property for the treatment of acute stroke.

No Comments